[go: up one dir, main page]

PL2035001T3 - Stabilne preparaty lakwinimodu - Google Patents

Stabilne preparaty lakwinimodu

Info

Publication number
PL2035001T3
PL2035001T3 PL07809468T PL07809468T PL2035001T3 PL 2035001 T3 PL2035001 T3 PL 2035001T3 PL 07809468 T PL07809468 T PL 07809468T PL 07809468 T PL07809468 T PL 07809468T PL 2035001 T3 PL2035001 T3 PL 2035001T3
Authority
PL
Poland
Prior art keywords
preparations
stable
stable laquinimod
laquinimod preparations
laquinimod
Prior art date
Application number
PL07809468T
Other languages
English (en)
Inventor
Shulamit Patashnik
Daniella Licht
Adrian Gilbert
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of PL2035001T3 publication Critical patent/PL2035001T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Composite Materials (AREA)
  • Mechanical Engineering (AREA)
PL07809468T 2006-06-12 2007-06-12 Stabilne preparaty lakwinimodu PL2035001T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81324706P 2006-06-12 2006-06-12
EP07809468A EP2035001B1 (en) 2006-06-12 2007-06-12 Stable laquinimod preparations
PCT/US2007/013721 WO2007146248A2 (en) 2006-06-12 2007-06-12 Stable laquinimod preparations

Publications (1)

Publication Number Publication Date
PL2035001T3 true PL2035001T3 (pl) 2012-05-31

Family

ID=38832466

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07809468T PL2035001T3 (pl) 2006-06-12 2007-06-12 Stabilne preparaty lakwinimodu

Country Status (27)

Country Link
US (3) US7989473B2 (pl)
EP (1) EP2035001B1 (pl)
JP (1) JP5226678B2 (pl)
KR (4) KR20160013273A (pl)
CN (1) CN101466379B (pl)
AR (1) AR061348A1 (pl)
AT (1) ATE532515T1 (pl)
AU (1) AU2007258366B2 (pl)
BR (1) BRPI0713694A2 (pl)
CA (2) CA2654982C (pl)
CY (1) CY1113003T1 (pl)
DK (1) DK2035001T3 (pl)
EA (1) EA018031B1 (pl)
ES (1) ES2377149T3 (pl)
HR (1) HRP20120093T1 (pl)
IL (1) IL195724A (pl)
MX (1) MX2008015808A (pl)
NO (1) NO342485B1 (pl)
NZ (1) NZ573846A (pl)
PL (1) PL2035001T3 (pl)
PT (1) PT2035001E (pl)
RS (1) RS52169B (pl)
SI (1) SI2035001T1 (pl)
TW (1) TWI400073B (pl)
UA (1) UA96449C2 (pl)
WO (1) WO2007146248A2 (pl)
ZA (1) ZA200810790B (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SI1937642T1 (sl) * 2005-10-19 2015-01-30 Teva Pharmaceutical Industries Ltd. Kristali natrijevega lakvinimoda in postopek za njihovo pripravo
AU2007258366B2 (en) 2006-06-12 2012-10-25 Active Biotech, Ab Stable laquinimod preparations
PL2234485T3 (pl) 2007-12-20 2014-06-30 Teva Pharma Stabilne preparaty lakwinimodu
UA104005C2 (ru) * 2008-09-03 2013-12-25 Тева Фармасьютикл Индастриз, Лтд. 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
DE102009008851A1 (de) 2009-02-13 2010-08-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102010048788A1 (de) 2009-02-13 2011-05-19 Amw Gmbh Transdermales System mit Immunmodulator
SG176840A1 (en) * 2009-06-19 2012-02-28 Teva Pharma Treatment of multiple sclerosis with laquinimod
PL2458992T3 (pl) * 2009-07-30 2016-07-29 Teva Pharma Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu
EP2467372B1 (en) 2009-08-10 2016-05-18 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
DK2542079T3 (da) * 2010-03-03 2014-08-25 Teva Pharma Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat
ES2601819T3 (es) * 2010-03-03 2017-02-16 Teva Pharmaceutical Industries Ltd. Tratamiento de la artritis lúpica usando laquinimod
ES2558556T3 (es) * 2010-03-03 2016-02-05 Teva Pharmaceutical Industries Ltd. Tratamiento de nefritis lúpica usando laquinimod
EA025377B1 (ru) 2010-07-09 2016-12-30 Тева Фармасьютикал Индастриз Лтд. Дейтерированный n-этил-n-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамид, его соли и их применение
EP2590653A4 (en) * 2010-07-09 2014-01-01 Teva Pharma 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROCHINOLINE-3-CARBOXAMIDE, SALT THEREOF AND APPLICATIONS THEREOF
US20120142730A1 (en) * 2010-12-07 2012-06-07 Nora Tarcic Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
CN103781354A (zh) * 2011-07-28 2014-05-07 泰华制药工业有限公司 用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症
CA2843432A1 (en) * 2011-07-28 2013-01-31 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and interferon-beta
JP2014530821A (ja) * 2011-10-12 2014-11-20 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドおよびフィンゴリモドを組み合わせた多発性硬化症の治療
CA2862865A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf.alpha. therapy
EP2744498A4 (en) 2012-02-16 2014-12-03 Teva Pharma N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-CHINOLINE CARBOXAMIDE AND THE PREPARATION AND USE THEREOF
US20130259856A1 (en) * 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
TW201350467A (zh) * 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
WO2014004733A1 (en) * 2012-06-26 2014-01-03 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
TW201410243A (zh) * 2012-08-13 2014-03-16 Teva Pharma 用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
TW201410244A (zh) * 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
EP2916915A4 (en) * 2012-11-07 2016-06-22 Teva Pharma LAQUINIMOD AMINE SALTS
CA2900503A1 (en) * 2013-02-15 2014-08-21 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod
HK1220125A1 (zh) 2013-03-14 2017-04-28 Teva Pharmaceutical Industries Ltd. 拉喹莫德的透皮配方
MX2015011627A (es) 2013-03-14 2016-05-16 Teva Pharma Cristales de laquinimod sodico y proceso mejorado para la elaboracion de los mismos.
WO2015065628A2 (en) * 2013-09-27 2015-05-07 Teva Pharmaceutical Industries Ltd. Laquinimod combination therapy for treatment of multiple sclerosis
KR20160110395A (ko) * 2013-12-20 2016-09-21 테바 파마슈티컬 인더스트리즈 리미티드 헌팅턴병 진행을 지연시키기 위한 라퀴니모드의 용도
EP3094330A4 (en) * 2014-01-17 2017-09-27 Teva Pharmaceutical Industries Ltd Treatment of crohn's disease using low doses of laquinimod
WO2015168103A1 (en) 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
CN110193014B (zh) * 2019-06-06 2021-05-11 温州医科大学 一种注射用拉喹莫德胶束冻干制剂及制备方法、拉喹莫德注射制剂

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3024257A (en) 1961-04-10 1962-03-06 Frosst & Co Charles E Stable preparations of alkali metal salts of estrone sulfate
FR2340735A1 (fr) 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
DE3437232A1 (de) * 1984-10-10 1986-04-17 Mack Chem Pharm Stabilisierte injektionsloesungen von piroxicam
SE8902076D0 (sv) 1989-06-09 1989-06-09 Pharmacia Ab Derivatives of quinoline-3-carboxanilide
HUT60458A (en) 1991-02-01 1992-09-28 Sandoz Ag Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same
US5540934A (en) 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
CH687615A5 (de) * 1994-09-07 1997-01-15 R W Johnson Pharmaceutical Res Tropen-Verpackung.
US5912349A (en) 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6133285A (en) 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
US6121287A (en) 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
TR200103527T2 (tr) 1999-06-07 2002-04-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Bir asit-labil aktif bileşik içeren yeni hazırlama ve uygulama şekli
RS51019B (sr) 1999-10-25 2010-10-31 Active Biotech Ab. Lekovi za lečenje malignih tumora
SE0002320D0 (sv) 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
JP2002031610A (ja) 2000-07-14 2002-01-31 Ajinomoto Co Inc 生体分子複合体の界面残基を同定する方法
US6307050B1 (en) 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US6802422B2 (en) 2000-12-12 2004-10-12 Multi-Comp, Inc. Sealed blister assembly
US6706733B2 (en) 2001-05-08 2004-03-16 Dainippon Ink And Chemicals, Inc. Quinolinone derivative formulation and its production method
US20030119826A1 (en) * 2001-09-24 2003-06-26 Pharmacia Corporation Neuroprotective treatment methods using selective iNOS inhibitors
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US6875869B2 (en) 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
US8980870B2 (en) * 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
EP1694308A1 (en) * 2003-10-30 2006-08-30 Lupin Ltd. Stable formulations of ace inhibitors and methods for preparation thereof
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
SI1937642T1 (sl) 2005-10-19 2015-01-30 Teva Pharmaceutical Industries Ltd. Kristali natrijevega lakvinimoda in postopek za njihovo pripravo
AU2007258366B2 (en) 2006-06-12 2012-10-25 Active Biotech, Ab Stable laquinimod preparations
US20080087929A1 (en) * 2006-10-11 2008-04-17 Infineon Technologies Ag Static random access memory with thin oxide capacitor
PL2234485T3 (pl) 2007-12-20 2014-06-30 Teva Pharma Stabilne preparaty lakwinimodu
UA104005C2 (ru) 2008-09-03 2013-12-25 Тева Фармасьютикл Индастриз, Лтд. 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
SG176840A1 (en) 2009-06-19 2012-02-28 Teva Pharma Treatment of multiple sclerosis with laquinimod
PL2458992T3 (pl) 2009-07-30 2016-07-29 Teva Pharma Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu
EP2467372B1 (en) 2009-08-10 2016-05-18 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
DK2542079T3 (da) 2010-03-03 2014-08-25 Teva Pharma Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat
ES2601819T3 (es) 2010-03-03 2017-02-16 Teva Pharmaceutical Industries Ltd. Tratamiento de la artritis lúpica usando laquinimod
ES2558556T3 (es) 2010-03-03 2016-02-05 Teva Pharmaceutical Industries Ltd. Tratamiento de nefritis lúpica usando laquinimod
EP2590653A4 (en) 2010-07-09 2014-01-01 Teva Pharma 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROCHINOLINE-3-CARBOXAMIDE, SALT THEREOF AND APPLICATIONS THEREOF
EA025377B1 (ru) 2010-07-09 2016-12-30 Тева Фармасьютикал Индастриз Лтд. Дейтерированный n-этил-n-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамид, его соли и их применение

Also Published As

Publication number Publication date
CA2899472A1 (en) 2007-12-21
KR20090017694A (ko) 2009-02-18
US20120302600A1 (en) 2012-11-29
JP2009539984A (ja) 2009-11-19
KR20160013273A (ko) 2016-02-03
KR20150065951A (ko) 2015-06-15
ZA200810790B (en) 2010-03-31
US20110251235A1 (en) 2011-10-13
PT2035001E (pt) 2012-02-06
HRP20120093T1 (hr) 2012-03-31
DK2035001T3 (da) 2012-02-27
ES2377149T3 (es) 2012-03-22
CN101466379B (zh) 2012-10-31
CA2654982C (en) 2015-11-10
CA2654982A1 (en) 2007-12-21
AU2007258366B2 (en) 2012-10-25
TWI400073B (zh) 2013-07-01
AR061348A1 (es) 2008-08-20
HK1121971A1 (en) 2009-05-08
JP5226678B2 (ja) 2013-07-03
US20070293537A1 (en) 2007-12-20
MX2008015808A (es) 2009-02-17
US8383645B2 (en) 2013-02-26
KR101495327B1 (ko) 2015-02-24
NZ573846A (en) 2012-01-12
AU2007258366A1 (en) 2007-12-21
NO342485B1 (no) 2018-05-28
CA2899472C (en) 2019-04-30
IL195724A0 (en) 2009-09-01
NO20090175L (no) 2009-03-11
EP2035001A2 (en) 2009-03-18
SI2035001T1 (sl) 2012-03-30
RS52169B (sr) 2012-08-31
US7989473B2 (en) 2011-08-02
UA96449C2 (en) 2011-11-10
EA018031B1 (ru) 2013-05-30
KR20140091778A (ko) 2014-07-22
IL195724A (en) 2015-09-24
CY1113003T1 (el) 2016-04-13
WO2007146248A3 (en) 2008-12-24
BRPI0713694A2 (pt) 2012-10-30
CN101466379A (zh) 2009-06-24
TW200815006A (en) 2008-04-01
ATE532515T1 (de) 2011-11-15
WO2007146248A2 (en) 2007-12-21
EP2035001A4 (en) 2009-09-23
EA200870599A1 (ru) 2009-06-30
EP2035001B1 (en) 2011-11-09

Similar Documents

Publication Publication Date Title
ZA200810790B (en) Stable laquinimod preparations
IL205855A0 (en) Stable laquinimod preparations
IL193265A0 (en) Quinoline derivatives
GB2435419B (en) Formulations
EP1988922A4 (en) PROTEIN FORMULATIONS
EP2046930A4 (en) FORMULATIONS BASED ON RHAMNOLIPIDS
IL194367A0 (en) Dihydropyrazolopyrimidinone derivatives
PL2069312T3 (pl) Pochodne pirydazynonu
IL195013A0 (en) Pyridopyrimidinone derivatives
PT2035394E (pt) Derivados de 2-pirazinocarboxamid
IL192401A0 (en) Indol-3-yl-carbonyl-spiro-piperidine derivatives
SI1912647T1 (sl) Antibakterijski derivati kinolina
GB0718409D0 (en) Formulations
GB0605780D0 (en) Formulations
IL198645A0 (en) 5-hydroxymethyl-oxazolidin-2-one derivatives
IL197152A0 (en) 5-phenyl-nicotinamide derivatives
GB0718346D0 (en) Tooth-bleaching preparations
GB0610336D0 (en) Formulations
IL197239A0 (en) Phenyloxyaniline derivatives
GB0610140D0 (en) Protein stability
GB0718404D0 (en) Formulations
GB0625671D0 (en) Protein formulation
AU4913P (en) KencoralGL Kennedia coccinea
ZA200806877B (en) Quinoline Derivatives
GB0616155D0 (en) Food preparations